Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
KYMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.07 - $53.27
Previous CloseN/A
Volume48.51K
Average Volume (3M)626.45K
Market Cap
$2.16B
Enterprise Value$3.14B
Total Cash (Recent Filing)$120.26M
Total Debt (Recent Filing)$87.76M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
May 01, 2025EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding64,944,140
10 Day Avg. Volume955,806
30 Day Avg. Volume626,452
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)45.90
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit66.73
Enterprise Value/Ebitda-14.53
Forecast
1Y Price Target
$58.83Price Target Upside67.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Kymera Therapeutics News
PremiumCompany Announcements
Kymera Therapeutics Grants Performance Stock Units to Executives
PremiumCompany Announcements
Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentKYMR is the front-runner among the increasingly competitive and strategically attractive landscape of STAT6 targeting therapies.
Intellectual PropertyKYMR seems to have covered their ground thoroughly with thousands of pages across the patents, underscoring their lead position in development of a STAT6 degrader.
Bears Say
Risk AssessmentAnalyst's recommendation is cautious on the risk/benefit profiles of lead assets given the high bar for success.
---
Ownership Overview
28.27% Insiders
30.51% Mutual Funds
0.06% Other Institutional Investors
28.02% Public Companies and
Individual Investors
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $29.07 and its highest was $53.27 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Kymera Therapeutics’s market cap is $2.16B.
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 48 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.775 by -$0.105.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -0.89.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 64,944,140 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.775. Following the earnings report the stock price went down -14.451%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Currently, no hedge funds are holding shares in KYMR
---
Kymera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.83 (67.61% Upside)
$58.83 (67.61% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 776.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $499.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.12%
12-Months-Change
Fundamentals
Return on Equity
-36.38%
Trailing 12-Months
Asset Growth
69.87%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics (KYMR) is a biotechnology company specializing in the development of targeted protein degradation therapies. The company focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins, addressing unmet medical needs in areas such as oncology, inflammation, and immunology. Kymera's proprietary technology platform, Pegasus, enables the identification and development of these targeted protein degraders.
---
KYMR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical progress and strategic initiatives, such as the advancement of STAT6 and TYK2 programs and the expansion of collaboration with Sanofi, which supports a positive outlook. However, increased operational costs and limited revenue diversification present challenges.Read More>---
KYMR Stock 12 Month Forecast
Average Price Target
$58.83
▲(67.61% Upside)
Technical Analysis
Bluebird Bio
―
Ultragenyx Pharmaceutical
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Arvinas Holding Company
―
Best Analysts Covering KYMR
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+35.22%
reiterated a buy rating 15 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +35.22% per trade.
---